Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
oxygen | inhalation (medicine gas) | N/A | |
nitrous oxide | inhalation | N/A | |
isoflurane | inhalation | N/A | |
halothane | inhalation | N/A |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
lidocaine + epinephrine (adrenaline) | Injection | 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial | |
lidocaine + epinephrine (adrenaline) | Injection | 1% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial | |
lidocaine | Injection for spinal anaesthesia | 5% (hydrochloride) in 2-ml ampoule to be mixed with 7.5% glucose solution | e |
lidocaine | topical forms | 2% to 4% (hydrochloride) | e |
lidocaine + epinephrine (adrenaline) | dental cartridge | 2% (hydrochloride) + epinephrine 1:80 000 | |
bupivacaine | Injection for spinal anaesthesia | 0.5% (hydrochloride) in 4-ml ampoule to be mixed with 7.5% glucose solution | e |
lidocaine | Injection | 1% (hydrochloride) in vial | e |
lidocaine | Injection | 2% (hydrochloride) in vial | e |
bupivacaine | Injection | 0.25% (hydrochloride) in vial | e |
bupivacaine | Injection | 0.5% (hydrochloride) in vial | e |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
ephedrine | Injection | 30 mg (hydrochloride)/ml in 1-ml ampoule |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
acetylsalicylic acid | Suppository | 50 mg to 150 mg | |
acetylsalicylic acid | tablet | 100 mg to 500 mg | |
ibuprofen | oral liquid | 200 mg/5 mL | a |
ibuprofen | tablet | 200 mg | a |
ibuprofen | tablet | 400 mg | a |
paracetamol | oral liquid | 125 mg/5 ml | |
paracetamol | Suppository | 100 mg | |
paracetamol | tablet | 100 mg to 500 mg |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
acetylsalicylic acid | Suppository | 50 mg to 150 mg | c1 |
acetylsalicylic acid | tablet | 100 mg to 500 mg | c1 |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
codeine | tablet | 30 mg (phosphate) | |
morphine | Injection | 10 mg (sulfate or hydrochloride) in 1-ml ampoule | |
morphine | oral liquid | 10 mg (hydrochloride or sulfate)/5 ml | |
morphine | tablet | 10 mg (morphine sulfate) | |
morphine | tablet (prolonged release) | 10 mg (morphine sulfate) | |
morphine | tablet (prolonged release) | 30 mg (morphine sulfate) | |
morphine | tablet (prolonged release) | 60 mg (morphine sulfate) |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
allopurinol | tablet | 100 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
chloroquine | tablet | 100 mg (as phosphate or sulfate) | |
chloroquine | tablet | 150 mg (as phosphate or sulfate) |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
azithromycin | powder for oral suspension | 200 mg | |
hydroxychloroquine | solid oral dosage form | 200 mg (as sulfate) | c1 |
methotrexate | tablet | 2.5 mg (as sodium salt) | |
penicillamine | solid oral dosage form | 250 mg | |
sulfasalazine | tablet | 500 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
chlorphenamine | Injection | 10 mg (hydrogen maleate) in 1-ml ampoule | a e |
chlorphenamine | oral liquid | 2 mg/5 ml (hydrogen maleate) | a c2 e |
chlorphenamine | tablet | 4 mg (hydrogen maleate) | a e |
dexamethasone | Injection | 4 mg/mL in 1-mL ampoule (as disodium phosphate salt) | |
epinephrine (adrenaline) | Injection | 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule | |
hydrocortisone | Powder for injection | 100 mg (as sodium succinate) in vial | |
prednisolone | oral liquid | 5 mg/mL | c2 e |
prednisolone | tablet | 5 mg | e |
prednisolone | tablet | 25 mg | e |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
charcoal, activated | Powder | N/A |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
acetylcysteine | Injection | 200 mg/ml in 10-ml ampoule | |
acetylcysteine | oral liquid | 10% | c2 |
acetylcysteine | oral liquid | 20% | c2 |
atropine | Injection | 1 mg (sulfate) in 1-ml ampoule | |
calcium gluconate | Injection | 100 mg/mL in 10-mL ampoule | |
methylthioninium chloride (methylene blue) | Injection | 10 mg/ml in 10-ml ampoule | |
naloxone | Injection | 400 mcg (hydrochloride) in 1-mL ampoule | |
penicillamine | solid oral dosage form | 250 mg | |
potassium ferric hexacyano-ferrate(II) - 2H20 (Prussian blue) | powder for oral administration | N/A | |
sodium nitrite | Injection | 30 mg/mL in 10-mL ampoule | |
sodium thiosulfate | Injection | 250 mg/mL in 50-mL ampoule |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
deferoxamine | Powder for injection | 500 mg (mesilate) in vial | |
dimercaprol | Injection in oil | 50 mg/mL in 2-mL ampoule | |
sodium calcium edetate | Injection | 200 mg/ml in 5-ml ampoule | |
succimer | solid oral dosage form | 100 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
carbamazepine | oral liquid | 100 mg/5 ml | |
carbamazepine | tablet (chewable) | 100 mg | |
carbamazepine | tablet (chewable) | 200 mg | |
carbamazepine | tablet (scored) | 100 mg | |
carbamazepine | tablet (scored) | 200 mg | |
diazepam | Gel | 5 mg/mL in 0.5-mL tubes | |
diazepam | Gel | 5 mg/mL in 2-mL tubes | |
diazepam | Gel | 5 mg/mL in 4-mL tubes | |
lorazepam | parenteral formulation | 2 mg/ml in 1-ml ampoule | e |
lorazepam | parenteral formulation | 4 mg/ml in 1-ml ampoule | e |
magnesium sulfate | Injection | 500 mg/mL in 2-mL ampoule | |
magnesium sulfate | Injection | 500 mg/mL in 10-mL ampoule | |
phenobarbital | Injection | 200 mg/mL (sodium) | |
phenobarbital | oral liquid | 15 mg/5 mL | |
phenobarbital | tablet | 15 mg to 100 mg | |
phenytoin | Injection | 50 mg/mL in 5-mL vial (sodium salt) | |
phenytoin | oral liquid | 25 mg to 30 mg/5 mL | |
phenytoin | solid oral dosage form | 25 mg (sodium salt) | |
phenytoin | solid oral dosage form | 50 mg (sodium salt) | |
phenytoin | solid oral dosage form | 100 mg (sodium salt) | |
phenytoin | tablet (chewable) | 50 mg | |
valproic acid (sodium valproate) | oral liquid | 200 mg/5 ml | |
valproic acid (sodium valproate) | tablet (crushable) | 100 mg | |
valproic acid (sodium valproate) | tablet (enteric-coated) | 200 mg (sodium valproate) | |
valproic acid (sodium valproate) | tablet (enteric-coated) | 500 mg (sodium valproate) | |
diazepam | rectal solution | 5 mg/mL in 0.5-mL tubes | |
diazepam | rectal solution | 5 mg/mL in 2-mL tubes | |
diazepam | rectal solution | 5 mg/mL in 4-mL tubes |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
ethosuximide | capsule | 250 mg | |
ethosuximide | oral liquid | 250 mg/5 ml |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
albendazole | tablet (chewable) | 400 mg | |
levamisole | tablet | 50 mg (as hydrochloride) | |
levamisole | tablet | 150 mg (as hydrochloride) | |
mebendazole | tablet (chewable) | 100 mg | |
mebendazole | tablet (chewable) | 500 mg | |
niclosamide | tablet (chewable) | 500 mg | |
praziquantel | tablet | 150 mg | |
praziquantel | tablet | 600 mg | |
pyrantel | oral liquid | 50 mg (as embonate or pamoate)/ml | |
pyrantel | tablet (chewable) | 250 mg (as embonate or pamoate) |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
albendazole | tablet (chewable) | 400 mg | |
diethylcarbamazine | tablet | 50 mg (dihydrogen citrate) | |
diethylcarbamazine | tablet | 100 mg (dihydrogen citrate) | |
ivermectin | tablet (scored) | 3 mg | |
ivermectin | tablet (scored) | 6 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
praziquantel | tablet | 600 mg | |
triclabendazole | tablet | 250 mg |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
oxamniquine | capsule | 250 mg | |
oxamniquine | oral liquid | 250 mg/5 ml |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
amoxicillin | powder for oral liquid | 125 mg (as trihydrate)/5 mL | |
amoxicillin | powder for oral liquid | 250 mg (as trihydrate)/5 mL | c2 |
amoxicillin | solid oral dosage form | 250 mg (as trihydrate) | |
amoxicillin | solid oral dosage form | 500 mg (as trihydrate) | |
amoxicillin + clavulanic acid | oral liquid | 125 mg amoxicillin + 31.25 mg clavulanic acid/5 ml | |
amoxicillin + clavulanic acid | oral liquid | 250 mg amoxicillin + 62.5 mg clavulanic acid/5 ml | c2 |
amoxicillin + clavulanic acid | tablet | 500 mg (as trihydrate) + 125 mg (as potassium salt) | |
ampicillin | Powder for injection | 500 mg (as sodium salt) in vial | |
ampicillin | Powder for injection | 1 g (as sodium salt) in vial | |
benzathine benzylpenicillin | Powder for injection | 900 mg benzylpenicillin (= 1.2 million IU) in 5-ml vial | c2 |
benzathine benzylpenicillin | Powder for injection | 1.44 g benzylpenicillin (= 2.4 million IU) in 5-ml vial | |
benzylpenicillin | Powder for injection | 600 mg (= 1 million IU) (sodium or potassium salt) in vial | |
benzylpenicillin | Powder for injection | 3 g (= 5 million IU) (sodium or potassium salt) in vial | |
cefalexin | powder for reconstitution with water | 125 mg/5 mL (anhydrous) | c2 |
cefalexin | powder for reconstitution with water | 250 mg/5 mL (anhydrous) | c2 |
cefazolin | Powder for injection | 1 g (as sodium salt) in vial | a e |
cefixime | capsule | 400 mg (as trihydrate) | |
ceftriaxone | Powder for injection | 250 mg (as sodium salt) in vial | a |
ceftriaxone | Powder for injection | 1 g (as sodium salt) in vial | a |
cloxacillin | capsule | 500 mg (as sodium salt) | e |
cloxacillin | capsule | 1 g (as sodium salt) | e |
cloxacillin | Powder for injection | 500 mg (as sodium salt) in vial | e |
cloxacillin | powder for oral liquid | 125 mg (as sodium salt)/5 mL | e |
phenoxymethylpenicillin | powder for oral liquid | 250 mg (as potassium salt)/5 ml | |
phenoxymethylpenicillin | tablet | 250 mg (as potassium salt) | |
procaine benzylpenicillin | Powder for injection | 1 g (=1 million IU) in vial | |
procaine benzylpenicillin | Powder for injection | 3 g (=3 million IU) in vial |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
cefotaxime | Powder for injection | 250 mg per vial (as sodium salt) | c1 |
ceftazidime | Powder for injection | 250 mg (as pentahydrate) in vial | |
ceftazidime | Powder for injection | 1 g (as pentahydrate) in vial | |
imipenem + cilastatin | Powder for injection | 250 mg (as monohydrate) + 250 mg (as sodium salt) in vial | |
imipenem + cilastatin | Powder for injection | 500 mg (as monohydrate) + 500 mg (as sodium salt) in vial |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
azithromycin | capsule | 250 mg (anhydrous) | |
azithromycin | capsule | 500 mg (anhydrous) | |
azithromycin | oral liquid | 200 mg/5 mL | |
chloramphenicol | capsule | 250 mg | |
chloramphenicol | Oily suspension for injection | 0.5 g (as sodium succinate)/ml in 2-ml ampoule | |
chloramphenicol | oral liquid | 150 mg (as palmitate)/5 mL | |
chloramphenicol | Powder for injection | 1 g (sodium succinate) in vial | |
ciprofloxacin | oral liquid | 250 mg/5 ml (anhydrous) | c2 e |
ciprofloxacin | Solution for IV infusion | 2 mg/ml (as hyclate) | c2 e |
ciprofloxacin | tablet | 250 mg (as hydrochloride) | e |
clarithromycin | solid oral dosage form | 500 mg | |
doxycycline | oral liquid | 25 mg/5 ml (anhydrous) | a c2 |
doxycycline | oral liquid | 50 mg/5 ml (anhydrous) | a c2 |
doxycycline | solid oral dosage form | 50 mg (as hyclate) | a c2 |
doxycycline | solid oral dosage form | 100 mg (as hyclate) | a |
erythromycin | Powder for injection | 500 mg (as lactobionate) in vial | e |
erythromycin | powder for oral liquid | 125 mg/5 mL (as stearate or estolate or ethyl succinate) | e |
erythromycin | solid oral dosage form | 250 mg (as stearate or estolate or ethyl succinate) | e |
gentamicin | Injection | 10 mg (sulfate)/mL in 2-mL vial | e |
gentamicin | Injection | 40 mg (sulfate)/ml in 2-mL vial | |
metronidazole | Injection | 500 mg in 100-mL vial | e |
metronidazole | oral liquid | 200 mg (as benzoate)/5 mL | e |
metronidazole | Suppository | 500 mg | e |
metronidazole | Suppository | 1 g | e |
metronidazole | tablet | 200 mg to 500 mg | e |
nitrofurantoin | oral liquid | 25 mg/5 ml | c2 |
nitrofurantoin | tablet | 100 mg | |
spectinomycin | Powder for injection | 2 g (as hydrochloride) in vial | |
sulfamethoxazole + trimethoprim | Injection | 80 mg + 16 mg/mL in 5-mL ampoule | |
sulfamethoxazole + trimethoprim | Injection | 80 mg + 16 mg/mL in 10-mL ampoule | |
sulfamethoxazole + trimethoprim | oral liquid | 200 mg + 40 mg/5 mL | |
sulfamethoxazole + trimethoprim | tablet | 100 mg + 20 mg | |
sulfamethoxazole + trimethoprim | tablet | 400 mg + 80 mg | |
sulfamethoxazole + trimethoprim | tablet | 800 mg + 160 mg | |
trimethoprim | oral liquid | 50 mg/5 ml | a c2 |
trimethoprim | tablet | 100 mg | a |
trimethoprim | tablet | 200 mg | a |
clindamycin | oral liquid | 75 mg/5 mL (as palmitate) | c2 |
vancomycin | Powder for injection | 250 mg (as hydrochloride) in vial |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
clindamycin | capsule | 150 mg (as hydrochloride) | |
clindamycin | Injection | 150 mg (as phosphate)/mL |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
clofazimine | capsule | 50 mg | |
clofazimine | capsule | 100 mg | |
dapsone | tablet | 25 mg | |
dapsone | tablet | 50 mg | |
dapsone | tablet | 100 mg | |
rifampicin | solid oral dosage form | 150 mg | |
rifampicin | solid oral dosage form | 300 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
ethambutol | oral liquid | 25 mg/ml | c2 |
ethambutol | tablet | 100 mg to 400 mg (hydrochloride) | |
ethambutol + isoniazid | tablet | 400 mg + 150 mg | |
ethambutol + isoniazid + pyrazinamide + rifampicin | tablet | 275 mg + 75 mg + 400 mg + 150 mg | |
ethambutol + isoniazid + rifampicin | tablet | 275 mg + 75 mg + 150 mg | |
isoniazid | oral liquid | 50 mg/5 ml | c2 |
isoniazid | tablet | 100 mg to 300 mg | |
isoniazid | tablet (scored) | 50 mg | |
isoniazid + pyrazinamide + rifampicin | tablet | 75 mg + 400 mg + 150 mg | |
isoniazid + pyrazinamide + rifampicin | tablet | 150 mg + 500 mg + 150 mg | |
isoniazid + rifampicin | tablet | 75 mg + 150 mg | |
isoniazid + rifampicin | tablet | 150 mg + 300 mg | |
isoniazid + rifampicin | tablet | 60 mg + 60 mg | |
isoniazid + rifampicin | tablet | 150 mg + 150 mg | |
pyrazinamide | oral liquid | 30 mg/ml | c2 |
pyrazinamide | tablet | 400 mg | |
pyrazinamide | tablet (dispersible) | 150 mg | |
pyrazinamide | tablet (scored) | 150 mg | |
rifabutin | capsule | 150 mg | |
rifampicin | oral liquid | 20 mg/ml | c2 |
rifampicin | solid oral dosage form | 150 mg | |
rifampicin | solid oral dosage form | 300 mg | |
streptomycin | Powder for injection | 1 g (as sulfate) in vial |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
amikacin | Powder for injection | 100 mg (as sulfate) in vial | |
amikacin | Powder for injection | 500 mg (as sulfate) in vial | |
amikacin | Powder for injection | 1 g (as sulfate) in vial | |
capreomycin | Powder for injection | 1 g (as sulfate) in vial | |
cycloserine | solid oral dosage form | 250 mg | |
ethionamide | tablet | 125 mg | |
ethionamide | tablet | 250 mg | |
kanamycin | Powder for injection | 1 g (as sulfate) in vial | |
ofloxacin | tablet | 200 mg | |
ofloxacin | tablet | 400 mg | |
p-aminosalicylic acid | granules | 4 g in sachet | |
p-aminosalicylic acid | tablet | 500 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
clotrimazole | vaginal cream | 1% | |
clotrimazole | vaginal cream | 10% | |
clotrimazole | vaginal tablet | 100 mg | |
clotrimazole | vaginal tablet | 500 mg | |
fluconazole | capsule | 50 mg | e |
fluconazole | Injection | 2 mg/mL in vial | e |
fluconazole | oral liquid | 50 mg/5 mL | e |
griseofulvin | oral liquid | 125 mg/5 ml | c2 |
griseofulvin | solid oral dosage form | 125 mg | |
griseofulvin | solid oral dosage form | 250 mg | |
nystatin | Lozenge | 100 000 IU | |
nystatin | oral liquid | 50 mg/5 ml | c2 |
nystatin | oral liquid | 100 000 IU/ml | c2 |
nystatin | pessary | 100 000 IU | |
nystatin | tablet | 100 000 IU | |
nystatin | tablet | 500 000 IU |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
amphotericin B | Powder for injection | 50 mg in vial | |
flucytosine | capsule | 250 mg | |
flucytosine | Infusion | 2.5 g in 250 ml | |
potassium iodide | saturated solution | N/A |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
abacavir (ABC) | oral liquid | 100 mg (as sulfate)/5 ml | |
abacavir (ABC) | tablet | 300 mg (as sulfate) | |
didanosine (ddI) | buffered powder for oral liquid | 100 mg packets | |
didanosine (ddI) | buffered powder for oral liquid | 167 mg packets | |
didanosine (ddI) | buffered powder for oral liquid | 250 mg packets | |
didanosine (ddI) | capsule (unbuffered enteric-coated) | 125 mg | |
didanosine (ddI) | capsule (unbuffered enteric-coated) | 200 mg | |
didanosine (ddI) | capsule (unbuffered enteric-coated) | 250 mg | |
didanosine (ddI) | capsule (unbuffered enteric-coated) | 400 mg | |
didanosine (ddI) | tablet (buffered chewable, dispersible) | 25 mg | |
didanosine (ddI) | tablet (buffered chewable, dispersible) | 50 mg | |
didanosine (ddI) | tablet (buffered chewable, dispersible) | 100 mg | |
didanosine (ddI) | tablet (buffered chewable, dispersible) | 150 mg | |
didanosine (ddI) | tablet (buffered chewable, dispersible) | 200 mg | |
emtricitabine (FTC) | capsule | 200 mg | a |
emtricitabine (FTC) | oral liquid | 10 mg/ml | a |
lamivudine (3TC) | oral liquid | 50 mg/5 ml | |
lamivudine (3TC) | tablet | 150 mg | |
stavudine (d4T) | capsule | 15 mg | |
stavudine (d4T) | capsule | 20 mg | |
stavudine (d4T) | capsule | 30 mg | |
stavudine (d4T) | powder for oral liquid | 5 mg/5 ml | |
tenofovir disoproxil fumarate | tablet | 300 mg | |
zidovudine (ZDV or AZT) | capsule | 100 mg | |
zidovudine (ZDV or AZT) | capsule | 250 mg | |
zidovudine (ZDV or AZT) | oral liquid | 50 mg/5 mL | |
zidovudine (ZDV or AZT) | Solution for IV infusion injection | 10 mg/mL in 20-mL vial | |
zidovudine (ZDV or AZT) | tablet | 300 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
efavirenz (EFV or EFZ) | capsule | 50 mg | a |
efavirenz (EFV or EFZ) | capsule | 100 mg | a |
efavirenz (EFV or EFZ) | capsule | 200 mg | a |
efavirenz (EFV or EFZ) | oral liquid | 150 mg/5 ml | a |
efavirenz (EFV or EFZ) | tablet | 600 mg | a |
nevirapine (NVP) | oral liquid | 50 mg/5 ml | |
nevirapine (NVP) | tablet | 200 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
atazanavir | solid oral dosage form | 100 mg (as sulfate) | a |
atazanavir | solid oral dosage form | 150 mg (as sulfate) | a |
atazanavir | solid oral dosage form | 300 mg (as sulfate) | a |
indinavir (IDV) | solid oral dosage form | 400 mg (as sulfate) | |
lopinavir + ritonavir (LPV/r) | capsule | 133.3 mg + 33.3 mg | |
lopinavir + ritonavir (LPV/r) | oral liquid | 400 mg + 100 mg/5 ml | |
lopinavir + ritonavir (LPV/r) | tablet (heat stable) | 100 mg + 25 mg | |
lopinavir + ritonavir (LPV/r) | tablet (heat stable) | 200 mg + 50 mg | |
ritonavir | oral liquid | 400 mg/5 ml | |
ritonavir | solid oral dosage form | 100 mg | |
ritonavir | tablet (heat stable) | 25 mg | |
ritonavir | tablet (heat stable) | 100 mg | |
saquinavir (SQV) | solid oral dosage form | 200 mg (as mesilate) | a |
saquinavir (SQV) | solid oral dosage form | 500 mg (as mesilate) | a |
efavirenz + emtricitabine + tenofovir | tablet | 600 mg + 200 mg + 300 mg | |
emtricitabine + tenofovir | tablet | 200 mg + 300 mg | |
lamivudine + nevirapine + stavudine | tablet | 150 mg + 200 mg + 30 mg | |
lamivudine + nevirapine + stavudine | tablet (dispersible) | 30 mg + 50 mg + 6 mg | c2 |
lamivudine + nevirapine + stavudine | tablet (dispersible) | 60 mg + 100 mg + 12 mg | c2 |
lamivudine + nevirapine + zidovudine | tablet | 30 mg + 50 mg + 60 mg | c2 |
lamivudine + nevirapine + zidovudine | tablet | 150 mg + 200 mg + 300 mg | |
lamivudine + zidovudine | tablet | 30 mg + 60 mg | c2 |
lamivudine + zidovudine | tablet | 150 mg + 300 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
oseltamivir | capsule | 30 mg (as phosphate) | |
oseltamivir | capsule | 45 mg (as phosphate) | |
oseltamivir | capsule | 75 mg (as phosphate) | |
oseltamivir | oral powder | 12 mg/mL | |
ribavirin | injection for intravenous administration | 800 mg in 10-ml phosphate buffer solution | |
ribavirin | injection for intravenous administration | 1 g in 10-ml phosphate buffer solution | |
ribavirin | solid oral dosage form | 200 mg | |
ribavirin | solid oral dosage form | 400 mg | |
ribavirin | solid oral dosage form | 600 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
diloxanide | tablet | 500 mg (furoate) | |
metronidazole | Injection | 500 mg in 100-mL vial | e |
metronidazole | oral liquid | 200 mg (as benzoate)/5 mL | e |
metronidazole | tablet | 200 mg to 500 mg | e |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
amphotericin B | Powder for injection | 50 mg in vial | |
miltefosine | solid oral dosage form | 10 mg | |
miltefosine | solid oral dosage form | 50 mg | |
paromomycin | solution for intramuscular injection | 750 mg of paromomycin base (as the sulfate) | |
sodium stibogluconate | Injection | 100 mg/ml, 1 vial = 30 ml | |
meglumine antimoniate | Injection | 30%, equivalent to approximately 8.1% antimony (pentavalent) in 5-ml ampoule |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
amodiaquine | tablet | 153 mg (as hydrochloride) | |
amodiaquine | tablet | 200 mg (as hydrochloride) | |
artemether | Oily injection | 80 mg/ml in 1-ml ampoule | |
artemether + lumefantrine | tablet | 20 mg + 120 mg | |
artemether + lumefantrine | tablet (dispersible) | 20 mg + 120 mg | c2 |
artesunate | Injection | ampoules, containing 60 mg anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution | |
artesunate | rectal dosage form | 50 mg capsules | c2 |
artesunate | rectal dosage form | 200 mg capsules | c2 |
artesunate | tablet | 50 mg | |
artesunate + amodiaquine | tablet | 25 mg + 67.5 mg | |
artesunate + amodiaquine | tablet | 50 mg + 135 mg | |
artesunate + amodiaquine | tablet | 100 mg + 270 mg | |
chloroquine | oral liquid | 50 mg (as phosphate or sulfate)/5 ml | |
chloroquine | tablet | 100 mg (as phosphate or sulfate) | |
chloroquine | tablet | 150 mg (as phosphate or sulfate) | |
doxycycline | capsule | 100 mg (as hydrochloride or hyclate) | |
doxycycline | tablet (dispersible) | 100 mg (as monohydrate) | |
mefloquine | tablet | 250 mg (hydrochloride) | |
primaquine | tablet | 7.5 mg (as diphosphate) | |
primaquine | tablet | 15 mg (as diphosphate) | |
quinine | Injection | 300 mg quinine hydrochloride/mL in 2-mL ampoule | |
quinine | tablet | 300 mg (quinine sulfate) | |
quinine | tablet | 300 mg (quinine bisulfate) | |
sulfadoxine + pyrimethamine | tablet | 500 mg + 25 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
mefloquine | tablet | 250 mg (hydrochloride) | |
proguanil | tablet | 100 mg (as hydrochloride) | |
chloroquine | oral liquid | 50 mg (as phosphate or sulfate)/5 ml | |
chloroquine | tablet | 150 mg (as phosphate or sulfate) | |
doxycycline | solid oral dosage form | 100 mg (as hydrochloride or hyclate) |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
sulfamethoxazole + trimethoprim | tablet | 400 mg + 80 mg | c2 |
sulfamethoxazole + trimethoprim | oral liquid | 200 mg + 40 mg/5 mL | c2 |
sulfamethoxazole + trimethoprim | tablet | 100 mg + 20 mg | |
sulfamethoxazole + trimethoprim | Injection | 80 mg + 16 mg/mL in 5-mL ampoule | |
sulfamethoxazole + trimethoprim | Injection | 80 mg + 16 mg/mL in 10-mL ampoule | |
sulfamethoxazole + trimethoprim | oral liquid | 200 mg + 40 mg/5 mL | c2 |
pyrimethamine | tablet | 25 mg | |
sulfadiazine | tablet | 500 mg |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
pentamidine | tablet | 300 mg (as isethionate) | |
pentamidine | tablet | 200 mg (as isethionate) |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
pentamidine | Powder for injection | 200 mg (isetionate) in vial | |
suramin sodium | Powder for injection | 1 g in vial |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
eflornithine | Injection | 200 mg (hydrochloride)/ml in 100-ml bottle | |
melarsoprol | Injection | 3.6% solution, 5-ml ampoule (180 mg of active compound) | |
nifurtimox | tablet | 120 mg |
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
melarsoprol | Injection | 3.6% solution, 5-ml ampoule (180 mg of active compound) | c1 |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
benznidazole | tablet | 100 mg | |
nifurtimox | tablet | 30 mg | |
nifurtimox | tablet | 120 mg | |
nifurtimox | tablet | 250 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
acetylsalicylic acid | tablet | 300 mg to 500 mg | |
ibuprofen | tablet | 200 mg | c2 |
ibuprofen | tablet | 400 mg | c2 |
paracetamol | oral liquid | 125 mg/5 ml | c2 |
paracetamol | tablet | 300 mg to 500 mg |
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
propranolol | tablet | 20 mg (hydrochloride) | e |
propranolol | tablet | 40 mg (hydrochloride) | e |
Medicine | Pharmaceutical form type | Composition | Observation |
---|
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
azathioprine | Powder for injection | 100 mg (as sodium salt) in vial | |
azathioprine | tablet (scored) | 50 mg | |
ciclosporin | capsule | 25 mg | |
ciclosporin | concentrate for injection | 50 mg/ml in 1-ml ampoule |
Medicine | Pharmaceutical form type | Composition | Observation |
---|
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
allopurinol | tablet | 100 mg | c1 |
allopurinol | tablet | 300 mg | c1 |
asparaginase | Powder for injection | 10 000 IU in vial | |
bleomycin | Powder for injection | 15 mg (as sulfate) in vial | |
calcium folinate | Injection | 3 mg/mL in 10-mL ampoule | |
calcium folinate | tablet | 15 mg | |
carboplatin | Injection | 50 mg/5 mL | e |
carboplatin | Injection | 150 mg/15 mL | e |
carboplatin | Injection | 450 mg/45 mL | e |
carboplatin | Injection | 600 mg/60 mL | e |
chlorambucil | tablet | 2 mg | |
cyclophosphamide | Powder for injection | 500 mg in vial | |
cyclophosphamide | tablet | 25 mg | |
cytarabine | Powder for injection | 100 mg in vial | |
dacarbazine | Powder for injection | 100 mg in vial | |
dactinomycin | Powder for injection | 500 mcg in vial | |
daunorubicin | Powder for injection | 50 mg (hydrochloride) in vial | |
docetaxel | Injection | 20 mg/ml | |
docetaxel | Injection | 40 mg/mL | |
doxorubicin | Powder for injection | 10 mg (hydrochloride) in vial | |
doxorubicin | Powder for injection | 50 mg (hydrochloride) in vial | |
etoposide | capsule | 100 mg | |
etoposide | Injection | 20 mg/mL in 5-mL ampoule | |
fluorouracil | Injection | 50 mg/ml in 5-ml ampoule | |
hydroxycarbamide | solid oral dosage form | 200 mg | |
hydroxycarbamide | solid oral dosage form | 250 mg | |
hydroxycarbamide | solid oral dosage form | 300 mg | |
hydroxycarbamide | solid oral dosage form | 400 mg | |
hydroxycarbamide | solid oral dosage form | 500 mg | |
hydroxycarbamide | solid oral dosage form | 1 g | |
ifosfamide | Powder for injection | 1 g in vial | |
ifosfamide | Powder for injection | 2 g in vial | |
mercaptopurine | tablet | 50 mg | |
mesna | Injection | 100 mg/ml in 4-ml ampoules | |
mesna | Injection | 100 mg/ml in 10-ml ampoules | |
mesna | tablet | 400 mg | |
mesna | tablet | 600 mg | |
methotrexate | Powder for injection | 50 mg (as sodium salt) in vial | |
methotrexate | tablet | 2.5 mg (as sodium salt) | |
paclitaxel | Powder for injection | 6 mg/ml | |
procarbazine | capsule | 50 mg (as hydrochloride) | |
thioguanine | solid oral dosage form | 40 mg | c1 |
vinblastine | Powder for injection | 10 mg (sulfate) in vial | |
vincristine | Powder for injection | 1 mg (sulfate) in vial | |
vincristine | Powder for injection | 5 mg (sulfate) in vial |
Medicine | Pharmaceutical form type | Composition | Observation |
---|
Complementary list
Medicine | Pharmaceutical form type | Composition | Observation |
---|---|---|---|
dexamethasone | Injection |